introduction

At Sequani we recognise the growing interest in biomarkers is not confined to the pharmaceutical industry.  Biomarker analysis can substantially enhance our understanding and prediction of toxicity.  Our biomarkers team has been established to provide a comprehensive, bespoke service   and includes two leading scientists in the field.

Biomarkers form a key component of our Biosciences division and is led by a pharmaceutical industry trained scientist (FIBMS) with over 25 years of experience in biomarkers and clinical pathology.

Mesoscale Discovery and Siemens immunoassay automated analyser technology are installed at Sequani and give access to wide-ranging assay menus in different species.  We also have extensive experience in development and validation of bespoke ELISA assays; supported by our automated ELISA plate readers and liquid handling system.

At Sequani, our approach to the application of biomarkers is based upon a scientific evaluation to enable selection of the most appropriate marker to address a specific safety issue.  The inclusion of biomarkers in a toxicology programme must also take account of the practical and scientific implications of collecting additional samples during the course of a study that may be submitted for regulatory review. Our scientific and technical specialists work closely with the Biomarker group to ensure the design of scientifically sound and technically feasible studies.

Study Types

• Initial feasibility studies
• Fit-for-purpose validation
• Analysis of study samples
• Method development